BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies Post author: Post published:October 6, 2023 Post category:uncategorized BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service. You Might Also Like Amid Medicaid ‘unwinding,’ many states wind up expansions August 16, 2024 Understanding the interplay between gut microbiota and vascular dysfunction January 30, 2024 MGI Tech’s DNBSEQ-E25 and G99 platforms set record for sequencing applications at high altitude June 7, 2024
MGI Tech’s DNBSEQ-E25 and G99 platforms set record for sequencing applications at high altitude June 7, 2024